Company intelligence / Profile preview

Spruce Biosciences, Inc.

South San Francisco, California, USAinvestors.sprucebio.com ↗

Ownership: Public · SPRB
Employees: ~50
Development stage: Phase 2

Overview

The company has experienced mixed clinical results. Their lead candidate tildacerfont failed in two Phase 2 trials for CAH in 2024 and has been discontinued. They have acquired tralesinidase alfa (TA-ERT) for MPS IIIB, which has shown promising results in normalizing HS and HS-NRE levels over a five-year period, with plans to submit a BLA in 2026.

Therapeutic areas: PsychiatryEndocrinologyWomen's HealthRare DiseasesNeurology
Modalities: Small moleculesBiologicsEnzyme replacement therapy
Industry: Biotech

Drug pipeline

6 assets

tralesinidase alfa

5 more assets in the full pipeline.

Request access →

Partnerships

HMNC (for MDD program)Kaken Pharmaceutical Co. Ltd.

Financials

Market cap: $149.6M
Total revenue: $0
Enterprise value: $61M

Beyond the preview

Go deeper on Spruce Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spruce Biosciences, Inc..

Explore the full profile